trimebutine

try-MEH-boo-teen

Therapeutic Classification: lower gastrointestinal tract motility regulators, spasmolytics

REMS

Therapeutic effects:

Absorption: Rapidly absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.

Half-Life: 2.7–3.1 hr.

(symptom relief)

ROUTE	ONSET	PEAK	DURATION
PO	within 3 days–2 wk	1 hr (blood level)	>1 wk (following discontinuation)

Contraindicated in:

Use Cautiously in:

CNS: dizziness, drowsiness, fatigue, headache

GI: diarrhea, dry mouth, dysgeusia, dyspepsia, epigastric pain, nausea

Derm: hot/cold sensation, rash

Drug-drug:

Assess for symptoms of irritable bowel syndrome (cramping, constipation and diarrhea, mucus in stools).
Assess for abdominal distention and assess bowel sounds.
Monitor intake and output and record.

Instruct patient to take trimebutine as directed.
Rep: Advise females of reproductive potential to inform health care professional if pregnancy is planned or suspected or if breastfeeding.

Modulon